Shots: The P-III GY004 study involves assessing of cediranib + Lynparza vs Lynparza as monothx. vs standard platinum-based CT in patients with recurrent platinum-sensitive OC, fallopian tube, or primary peritoneal […]readmore
Tags : Platinum-Sensitive
Shots: The P-III SOLO3 study results involves assessing of Lynparza (300mg, bid) vs CT (paclitaxel/topotecan /pegylated liposomal doxorubicin/gemcitabine) in 266 patients in a ratio (2:1) with 2L+ platinum-sensitive relapsed BRCA1/2-mutated […]readmore